Page last updated: 2024-12-10

l 365260

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 365260: a CCK-B antagonist; structure given in first source; potent & selective CCK-B & gastrin receptor ligand; L 365260 and L 365346 are (R)- and (S)-stereoisomers, respectively [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9887120
CHEMBL ID70380
SCHEMBL ID9843248
MeSH IDM0162246
PubMed CID5311201
CHEBI ID79548
SCHEMBL ID5931098
MeSH IDM0162246

Synonyms (42)

Synonym
OPREA1_464839
l 365346
PDSP2_000868
PDSP1_000882
1-[(3s)-1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
CHEMBL70380 ,
bdbm50061220
1-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea((s)l365_260)
1-((s)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1h-benzo[e][1,4]diazepin-3-yl)-3-m-tolyl-urea
SCHEMBL9843248
(3s)-1-methyl-3-[3-(3-methylphenyl)ureido]-5-phenyl-1h-1,4-benzodiazepin-2(3h)-one
urea, n-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)-, (s)-
118101-08-9
(s)-l 365260
PDSP2_000907
l 365,260
l 365260
l-365,260
n-[(3r)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl]-n'-(3-methylphenyl)urea
l-365260
118101-09-0
l365260
PDSP1_000921
1-[(3r)-1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea
chebi:79548 ,
bdbm81962
s-l-365,260
unii-370jhf4586
urea, n-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)-, (r)-
370jhf4586 ,
n-((3r)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)urea
SCHEMBL5931098
AKOS024457284
KDFQABSFVYLGPM-QFIPXVFZSA-N ,
(r)-n-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl)-n'-(3-methylphenyl)-urea
J-003705
NCGC00371056-01
Q27148659
MS-26737
HY-106840
CS-0026693
n-[(3r)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1h-1,4-benzodiazepin-3-yl]-n'-(3-methylphenyl)-urea

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" L-365,260 was rapidly absorbed and a biphasic pattern of elimination was demonstrated with a terminal half-life (t1/2) of 8 to 12 hours."( Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonist.
Clarke, L; Freedholm, D; Grasing, K; Lin, J; Murphy, MG; Putnam, K; Seibold, JR; Swigar, M; Weingartner, H; Wolkowitz, OM; Zhang, J, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
" The bioavailability for rats, dogs, and monkeys was approximately 14%, 9%, and 2%, respectively."( Physiological disposition and metabolism of L-365,260, a potent antagonist of brain cholecystokinin receptor, in laboratory animals.
Chen, IW; Dorley, JM; Lin, JH; Pitzenberger, SM; Ramjit, HG,
)
0.13
" Discovery of the natural product Asperlicin provided a new class of non-peptidal CCK antagonists, but oral bioavailability in this class remained elusive."( Molecular design of potent specific antagonists for the gastrin and cholecystokinin receptors.
Evans, BE, 1991
)
0.28
"The effects of the CCKB receptor antagonists L-365,260, CI-988 and L-740,093, a new compound with improved bioavailability and CNS penetration, were assessed for anxiolytic-like effects in three rat anxiolytic screens sensitive to benzodiazepines, the elevated plus maze (EPM), conditioned suppression of drinking (CSD) and conditioned emotional response (CER) tests."( Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.
Curnow, R; Dawson, GR; Iversen, SD; Rupniak, NM; Stanhope, KJ; Tricklebank, MD; Tye, S, 1995
)
0.29
" (3R)-N-[1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyri dyl) -1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N-[1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5- (2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl ]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21nmol/kg po in dogs."( (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Akuzawa, S; Batt, AR; Kendrick, DA; Miyata, K; Nishida, A; Ohta, M; Rooker, DP; Ryder, H; Satoh, M; Semple, G; Szelke, M, 1997
)
0.3
" The absolute oral bioavailability of compound 61 was 22% in rats."( Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
Field, M; Hinton, J; Meecham, K; Pablo, J; Padia, JK; Pinnock, R; Roth, BD; Singh, L; Suman-Chauhan, N; Trivedi, BK; Webdale, L, 1998
)
0.3
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Data revealed that, in mice, the CCKA receptor antagonist, devazepide (formerly L-364,718, MK-329), produced a clear anxiolytic-like profile with an inverted U-shaped dose-response curve centered around 5 micrograms/kg."( The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.
Dourish, CT; Hendrie, CA; Neill, JC; Shepherd, JK, 1993
)
0.29
"3 mg/kg) which shifted the dose-response curve to the right."( An investigation into the discriminative stimulus and reinforcing properties of the CCKB-receptor antagonist, L-365,260 in rats.
Bentley, G; Bourson, A; Hargreaves, R; Iversen, S; Jackson, A; Rycroft, W; Tattersall, D; Tricklebank, M, 1994
)
0.29
" Dose-response studies indicated the following rank order of potency: Suc-CCK-7 > or = Suc-(Thr28, Leu29, MePhe33)-CCK-7 > or = CCK-8 > or = (Nle28,31)-CCK-8 >> desulfated CCK-8 = CCK-4 = 0 in the case of ip administration and Suc-(Thr28, Leu29, MePhe33)-CCK-7 >> Suc-CCK-7 > or = CCK-8 > or = (Nle28,31)-CCK-8 >> desulfated CCK-8 = CCK-4 = 0 in the case of icv administration."( Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice.
Baba, S; Himori, N; Hirosue, Y; Inui, A; Kasuga, M; Miura, M; Nakajima, M; Nakajima, Y; Okita, M; Teranishi, A, 1993
)
0.29
" Dose-response curves for the enhancement of the two drugs on morphine analgesia were bell-shaped."( [Potentiation of morphine- and ohmefentanyl-induced analgesia by cholecystokinin receptor antagonists in rat].
Han, JS; Sun, YH; Zhou, Y, 1993
)
0.29
" Both devazepide and L-365,260 showed a bell-shaped dose-response curve."( Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord.
Han, JS; Sun, YH; Zhang, ZW; Zhou, Y, 1993
)
0.29
" In a follow-up study, YM022 and RP73870 were found to produce a rightward shift of the gastrin dose-response curve, which is consistent with competitive inhibition."( Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
Ding, XQ; Håkanson, R, 1996
)
0.29
" In the first set, the aim of the experiments was to investigate the dose-response effect of selective serotonin re-uptake inhibitor (SSRI) citalopram on rat exploratory behaviour in the elevated plus-maze."( The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat.
Allikmets, L; Harro, J; Matto, V, 1996
)
0.52
" The dose-response curve for the three drugs was biphasic, suggesting that other mechanisms are operative at higher doses."( Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
Ballaz, S; Barber, A; Del Río, J; Fortuño, A; García-López, MT; Gómez-Monterrey, I; González-Muñiz, R; Herranz, R; Martin-Martínez, M, 1997
)
0.3
" Dose-response experiments revealed the following potencies for SOM secretion: G-17s = CCK-8s > G-17 ns >> CCK-8ns."( Cholecystokinin (CCK) regulates somatostatin secretion through both the CCK-A and CCK-B/gastrin receptors in sheep.
Shulkes, A; Zavros, Y, 1997
)
0.3
", necessity of an anxiogenic baseline, drug and receptor specificity, as well as the dose-response nature of the interaction, were discussed."( The inability of CCK to block (or CCK antagonists to substitute for) the stimulus effects of chlordiazepoxide.
Fox, MA; Levine, ES; Riley, AL,
)
0.13
" CCK in the RVM also acutely displaced the spinal morphine antinociceptive dose-response curve to the right."( Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.
Gardell, LR; Herman, DS; Lai, J; Ossipov, MH; Porreca, F; Stiller, CO; Vanderah, TW; Xie, JY, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.48660.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency11.98770.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency11.98770.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.00360.00000.43624.3000AID53029; AID53039; AID53042
Histamine H1 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)10.00000.00151.307210.0000AID79875
Gastrin/cholecystokinin type B receptorHomo sapiens (human)IC50 (µMol)0.28000.00010.36154.0000AID50816
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)10.00000.00091.901410.0000AID79875
Cysteinyl leukotriene receptor 2Homo sapiens (human)IC50 (µMol)10.00000.00102.405210.0000AID79875
Cysteinyl leukotriene receptor 1Homo sapiens (human)IC50 (µMol)10.00000.00030.948710.0000AID79875
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.00810.00040.629810.0000AID50821
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.00810.00040.908610.0000AID50821
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.49810.00000.43624.3000AID50495; AID52892; AID52896; AID52911; AID52916; AID52919; AID53029; AID53031; AID53038; AID53039; AID53042; AID53051
Cholecystokinin receptor type ARattus norvegicus (Norway rat)Ki0.00010.00010.27892.8900AID50518
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03900.00010.24801.4000AID43077; AID51442
Gastrin/cholecystokinin type B receptorRattus norvegicus (Norway rat)Ki0.07850.00060.11960.6800AID43080; AID51462; AID51613
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00810.00040.615610.0000AID50821
Histamine H1 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)5.00000.00151.307210.0000AID79875
Cholecystokinin receptor type AHomo sapiens (human)IC50 (µMol)0.15850.00010.30381.9000AID52750
Cholecystokinin receptor type AHomo sapiens (human)Ki0.17380.00000.31902.2760AID262761
Gastrin/cholecystokinin type B receptorHomo sapiens (human)IC50 (µMol)0.00790.00010.36154.0000AID253527; AID253528; AID402082; AID50686; AID50815; AID50816; AID50821; AID50825; AID50837; AID51096; AID51615
Gastrin/cholecystokinin type B receptorHomo sapiens (human)Ki0.00770.00010.03660.3450AID262760; AID411818; AID411822; AID50959; AID50965; AID51102
Gastrin/cholecystokinin type B receptorMus musculus (house mouse)Ki0.00370.00030.01660.0940AID51284
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)5.00000.00091.901410.0000AID240820; AID79875
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)IC50 (µMol)0.04400.00041.13803.5000AID52568; AID52570
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)Ki0.39200.00030.13770.6310AID312995; AID52732
Cysteinyl leukotriene receptor 2Homo sapiens (human)IC50 (µMol)5.00000.00102.405210.0000AID79875
Cysteinyl leukotriene receptor 1Homo sapiens (human)IC50 (µMol)5.00000.00030.948710.0000AID79875
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (92)

Processvia Protein(s)Taxonomy
gastric acid secretionGastrin/cholecystokinin type B receptorHomo sapiens (human)
cell surface receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cell population proliferationGastrin/cholecystokinin type B receptorHomo sapiens (human)
cholecystokinin signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
pH reductionGastrin/cholecystokinin type B receptorHomo sapiens (human)
digestive tract developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
gland developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
neuron migrationCholecystokinin receptor type AHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayCholecystokinin receptor type AHomo sapiens (human)
axonogenesisCholecystokinin receptor type AHomo sapiens (human)
forebrain developmentCholecystokinin receptor type AHomo sapiens (human)
cholecystokinin signaling pathwayCholecystokinin receptor type AHomo sapiens (human)
G protein-coupled receptor signaling pathwayCholecystokinin receptor type AHomo sapiens (human)
cellular response to hormone stimulusCholecystokinin receptor type AHomo sapiens (human)
regulation of hormone secretionCholecystokinin receptor type AHomo sapiens (human)
gastric acid secretionGastrin/cholecystokinin type B receptorHomo sapiens (human)
cell surface receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGastrin/cholecystokinin type B receptorHomo sapiens (human)
positive regulation of cell population proliferationGastrin/cholecystokinin type B receptorHomo sapiens (human)
cholecystokinin signaling pathwayGastrin/cholecystokinin type B receptorHomo sapiens (human)
pH reductionGastrin/cholecystokinin type B receptorHomo sapiens (human)
digestive tract developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
gland developmentGastrin/cholecystokinin type B receptorHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
cholecystokinin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
protein bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
gastrin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
peptide hormone bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
type B gastrin/cholecystokinin receptor bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cholecystokinin receptor activityCholecystokinin receptor type AHomo sapiens (human)
peptide hormone bindingCholecystokinin receptor type AHomo sapiens (human)
peptide bindingCholecystokinin receptor type AHomo sapiens (human)
cholecystokinin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
protein bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
gastrin receptor activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
peptide hormone bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
type B gastrin/cholecystokinin receptor bindingGastrin/cholecystokinin type B receptorHomo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activityGastrin/cholecystokinin type B receptorHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
intracellular membrane-bounded organelleGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleoplasmCholecystokinin receptor type AHomo sapiens (human)
cytosolCholecystokinin receptor type AHomo sapiens (human)
plasma membraneCholecystokinin receptor type AHomo sapiens (human)
membraneCholecystokinin receptor type AHomo sapiens (human)
plasma membraneCholecystokinin receptor type AHomo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
intracellular membrane-bounded organelleGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membraneGastrin/cholecystokinin type B receptorHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (104)

Assay IDTitleYearJournalArticle
AID53039Inhibition of binding of [125I]CCK-8 to cholecystokinin type A receptor in rat pancreatic tissue1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID233258Selectivity ratio between CCK-B and CCK-A receptor1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID234648Selectivity ratio of IC50 of CCK1 to that of CCK22000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
AID53029Half maximal inhibition of specific binding of [125I]-Bolton-Hunter CCK-8 to Cholecystokinin type A receptor in the rat pancreas2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
AID50816Inhibition of binding of [125I]-CCK-8 to the cholecystokinin type B receptor1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID79875Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]
AID51118Half maximal inhibition of specific binding of [125I]Bolton-Hunter CCK-8 to Cholecystokinin type B receptor in the mouse cerebral cortex2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
AID50685Half maximal inhibition of binding of [125I]CCK-8 to Cholecystokinin type B receptor in guinea pig cerebral cortex.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID50819Displacement of [125 I] CCK-8 from Cholecystokinin type B receptor of guinea pig cerebral cortex1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
AID74344Displacement of 125 I-gastrin from gastrin receptor of guinea pig gastric glands1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
AID53042Displacement of [125 I] CCK-8 from Cholecystokinin type A receptor of rat pancreas1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
AID79876Inhibition of Iks current in isolated guinea pig myocytes during a 1s voltage clamp step from -50 to +50 mV.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]
AID411818Displacement of [125I]CCK-26-33 from CCK2 receptor expressed in CHO cells2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
AID53031Half-maximal inhibition of specific binding of [125I]bolton hunter CCK-8 to rat pancreas cholecystokinin type A receptor1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
AID43077Inhibitory activity against CCK-B receptor1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid.
AID262760Displacement of [125I]BH-CCK-8S from human recombinant CCK2 receptor expressed in NIH3T3 cells2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
AID235044Inhibition of [125I]-labeled CCK-8 sulfate binding to Cholecystokinin type B receptor in guinea pig brain membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolinone cholecystokinin-B receptor ligands.
AID52892Binding affinity towards Cholecystokinin type A receptor (CCK-A) receptor from rat pancreas using [125I]bolton Hunter CCK-8 as radioligand1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
AID50821In vitro affinity to the cholecystokinin type B receptor in guinea pig cortex assayed using [125I]BH-CCK-8 as radioligand1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.
AID234648Selectivity ratio of IC50 of CCK1 to that of CCK22000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
AID52570In vitro binding affinity for the cholecystokinin type A receptor in guinea pig pancreas assayed using [125I]BH-CCK-8 as radioligand1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.
AID50815Inhibition of Cholecystokinin type B receptor induced guinea pig gall bladder contractions when given intravenously2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
AID312995Displacement of [125I]BH-CCK-8S from CC1 receptor expressed in guinea pig pancreatic cells2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points.
AID79876Inhibition of Iks current in isolated guinea pig myocytes during a 1s voltage clamp step from -50 to +50 mV.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]
AID411822Displacement of [125I]CCK-26-33 from CCK2R-MOPR coexpressed in CHO cells2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
AID51113Inhibition of binding of [125I]Bolton-Hunter labeled CCK-8 to cholecystokinin type B receptor in the mouse cerebral cortex1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
AID50816Inhibition of binding of [125I]-CCK-8 to the cholecystokinin type B receptor1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID50661Intravenous activity against Cholecystokinin type B receptor antagonist in gastric fistula dog at dose 10 uM/kg1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.
AID262761Displacement of [3H]L-364718 from human recombinant CCK1 receptor expressed in PC3 cell line2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
AID53039Inhibition of binding of [125I]CCK-8 to cholecystokinin type A receptor in rat pancreatic tissue1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID52911Inhibition of [125 I]BH CCK-8S binding to Cholecystokinin type A receptor in pancreatic tissue1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
AID475043Induction of receptor internalization in YFP-tagged CCK2 receptor expressed in CHO cells2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.
AID411823Binding affinity to CCK2R-MOPR coexpressed in CHO cells assessed per mg of protein by [125I] CCK-26-33 displacement assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
AID53038Inhibition of binding of [125I]- CCK-33 to rat pancreas1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID43080Capacity to inhibit [3H]-p CCK 8 binding to membrane preparations of CHO cells transfected with the rat CCK-B receptor1998Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11
Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid.
AID51096Displacement of CCK-8 from human Cholecystokinin type B receptor expressing CHO cell membranes 1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
AID402082Inhibition of cholecystokinin B receptor1998Journal of natural products, Aug, Volume: 61, Issue:8
Recent natural products based drug development: a pharmaceutical industry perspective.
AID235045Inhibition of [125I]-labeled CCK-8 sulfate binding to Cholecystokinin type B receptor in mouse brain membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolinone cholecystokinin-B receptor ligands.
AID51284Tested for its receptor affinity from competition with 20 pM [125I]BH-CCK-8S for Cholecystokinin type B receptor binding sites in mouse cortical homogenates1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.
AID50837The concentration required for half maximal inhibition of the binding to Cholecystokinin type B receptor (CCK-B) from guinea pig cortical membrane1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
AID52896Evaluated for inhibition of cholecystokinin type A receptor by displacing [125I]bolton hunter CCK-8 radioligand in the rat pancreas1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
AID52919Concentration required for 50% inhibition of Cholecystokinin type A receptor in rat pancreatic tissue2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
AID197537Tested in gastric acid secretion assay by single shifts of pentagastrin concentration-effect curves in the isolated lumen-perfused immature rat stomach; Inactive at the concentration of 10e-5 M1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.
AID50965Inhibition by displacing [3H]CCK-8S against Cholecystokinin type B receptor of guinea pig2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
AID53042Displacement of [125 I] CCK-8 from Cholecystokinin type A receptor of rat pancreas1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
AID50495Inhibition of ligand binding to Cholecystokinin type A receptor from rat pancreatic tissue.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
AID50685Half maximal inhibition of binding of [125I]CCK-8 to Cholecystokinin type B receptor in guinea pig cerebral cortex.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]
AID51285Displacement of binding of [125I]CCK-8S to Cholecystokinin type B receptor in mouse cerebral cortex homogenates2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists.
AID475045Displacement of [125I]CCK from human YN-tagged CCK1 receptor expressed in CHO cells2010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.
AID50966Inhibition of binding of [125I]gastrin to Cholecystokinin type B receptor from guinea pig gastric glands1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID79875Inhibition of Ikr current in isolated guinea pig myocytes during a 0.5 s voltage clamp step from -50 to -10 mV.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]
AID21985The solubility is evaluated at a pH 0f 7.41996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
AID52732Tested for its receptor affinity from competition with 20 pM [125I]BH-CCK-8S for Cholecystokinin type A receptor binding sites on guinea pig-pancreatic cells1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane.
AID411819Binding affinity to CCK2 receptor expressed in CHO cells assessed per mg of protein2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
AID51610In vitro binding affinity for pentagastrin by Cholecystokinin type B receptor, assayed by pentagastrin stimulated acid secretion in an isolated perfused rat stomach2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists.
AID253528Inhibitory concentration against Cholecystokinin B receptor2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID51118Half maximal inhibition of specific binding of [125I]Bolton-Hunter CCK-8 to Cholecystokinin type B receptor in the mouse cerebral cortex2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
AID50518Inhibition by displacing [3H]CCK-8S against Cholecystokinin type A receptor of rat pancreatic membranes2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
AID233258Selectivity ratio between CCK-B and CCK-A receptor1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID51613Inhibition by displacing [3H]CCK-8S against Cholecystokinin type B receptor of rat pancreatic membranes2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
AID50510Inhibition ratio on CCK-A receptor with respect to CCK-B receptor1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
AID52568Inhibition of binding of [125I]- CCK-33 to guinea pig cortex1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID240820Inhibitory concentration against IKr potassium channel2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
AID52916Inhibition of binding of [125I]Bolton-Hunter labeled CCK-8 to cholecystokinin type A receptor in the rat pancreas.1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
AID253527Inhibitory concentration against gastrin receptor2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID50950Displacement of [3H]pCCK-8 from cholecystokinin type B receptor in guinea pig brain membrane1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
AID21692Bioavailability in rat after 120 minutes at an oral dose of 2.5 mg/kg1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID234374Selectivity ratio is IC50 value of CCK-A receptor to that of CCK-B receptor1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
AID50686Inhibition of [125 I]BH CCK-8S binding to Cholecystokinin type B receptor in guinea pig cortical membranes1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
AID51107Evaluated for inhibition of cholecystokinin type B receptor by displacing [125I]-Bolton hunter CCK-8 radioligand in the mouse cerebral cortex1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Rationally designed "dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988.
AID50825Binding activity against Cholecystokinin type B receptor from guinea pig cortex using [125]BH CCK-8s as radioligand.1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group.
AID231512Ratio of binding affinity towards CCK-B receptor to that of CCK-A receptor1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
AID51457Affinity of compound on binding of [3H]pCCK-8 to the cholecystokinin type B receptor in rat brain membrane1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
AID312994Antagonist activity at CCK2 receptor in stomach-lumen perfused immature rat2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points.
AID225310In vitro antagonistic activity of compound in rat hippocampus1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID51102Inhibition by displacing [3H]CCK-8S against human Cholecystokinin type B receptor2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
AID50819Displacement of [125 I] CCK-8 from Cholecystokinin type B receptor of guinea pig cerebral cortex1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
AID234480Ratio between the IC50 values of CCK-A and CCK-B1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
AID52750Displacement of CCK-8 from CHO cell membranes expressing human Cholecystokinin type A receptor1995Journal of medicinal chemistry, Jan-06, Volume: 38, Issue:1
CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
AID51104Binding affinity towards Cholecystokinin type B receptor (CCK-B) receptor in mouse cerebral cortex using [125I]bolton Hunter CCK-8 as radioligand1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists.
AID50662Intravenous activity against Cholecystokinin type B receptor antagonist in gastric fistula dog at dose 4 uM/kg1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.
AID51442Inhibition of inositol phosphate production induced by Cholecystokinin type B receptor (0.5 nM)1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
AID53029Half maximal inhibition of specific binding of [125I]-Bolton-Hunter CCK-8 to Cholecystokinin type A receptor in the rat pancreas2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
AID50959Compound was tested for the affinity against Cholecystokinin type B receptor on guinea pig cortex.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
AID262758Affinity for CCK2 receptor assessed by inhibition of pentagastrin-stimulated acid secretion in perfused rat stomach2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
AID74344Displacement of 125 I-gastrin from gastrin receptor of guinea pig gastric glands1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
AID51615Antagonistic activity against cholecystokinin type B receptor1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Excursions in drug discovery.
AID185620inhibition of the pentagastrin stimulated acid secretion in anesthetized rats at dose 1.0 umol/kg2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists.
AID51122Inhibition of [125I]-labeled CCK-8 sulfate binding to CCK-B receptor in mouse brain membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolinone cholecystokinin-B receptor ligands.
AID21691Bioavailability in rat after 30 minutes at an oral dose of 2.5 mg/kg1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
AID50813Inhibition of [125I]-labeled CCK-8 sulfate binding to CCK-B receptor in guinea pig brain membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolinone cholecystokinin-B receptor ligands.
AID53051Binding activity against Cholecystokinin type A receptor from rat pancreas using [125]BH CCK-8s as radioligand.1994Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group.
AID74347Inhibition of [125I]-labeled gastrin binding to gastrin receptor in guinea pig brain membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Quinazolinone cholecystokinin-B receptor ligands.
AID51120Half-maximal inhibition of specific binding of [125I]bolton hunter CCK-8 to mouse cerebral cortex cholecystokinin type B receptor1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
AID50512Ratio calculated as IC50 ratio of CCK-A to that of CCK-B1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
AID51462Compound was tested for binding affinity against rat brain Cholecystokinin type B receptor expressed in CHO cells.1997Journal of medicinal chemistry, Nov-21, Volume: 40, Issue:24
Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells.
AID51614Intravenous activity against Cholecystokinin type B receptor antagonist in Gosh and Schild rat at a dose of 1 umol/kg1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (401)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (1.25)18.7374
1990's300 (74.81)18.2507
2000's85 (21.20)29.6817
2010's9 (2.24)24.3611
2020's2 (0.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.84 (24.57)
Research Supply Index6.07 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials10 (2.37%)5.53%
Reviews0 (0.00%)6.00%
Reviews9 (2.13%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.24%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other402 (95.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]